49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia

Key Takeaways Explain This Topic AI

Diabetic Ketoacidosis (DKA) is triggered by absolute insulin deficiency and uninhibited lipolysis generating beta-hydroxybutyrate and acetoacetate, presenting acutely (<24 hours) with glucose usually >=200 mg/dL (or known diabetes at any glucose), arterial pH <7.30, serum bicarbonate <18 mEq/L, elevated anion gap >10-12, and positive ketones; Hyperosmolar Hyperglycemic State (HHS) involves relative insulin deficiency preventing ketogenesis, presenting insidiously over days to weeks with extreme glucose >600 mg/dL, serum osmolality >320 mOsm/kg, profound fluid deficits of 8-10 L, and minimal acidosis.

Potassium management is the paramount safety rule in hyperglycemic crises: if serum K+ is <3.5 mEq/L, insulin MUST BE HELD and potassium repleted (about 10 mEq/h) until K+ >3.5 mEq/L to avoid fatal cardiac arrhythmias and respiratory muscle weakness; if K+ is 3.5-5.0 mEq/L, add 20-30 mEq K+ per liter of IV fluid; if K+ >5.0 mEq/L, initiate insulin and start potassium once it falls below 5.0 (2024 adult consensus).

Fluid resuscitation begins with isotonic saline or a balanced crystalloid (500-1,000 mL/h for the first 2-4 hours in adults without renal or cardiac compromise), then fluids are chosen by hydration status and sodium; add 5-10% dextrose to IV fluids once blood glucose falls <250 mg/dL in DKA (or <300 mg/dL in HHS) while continuing insulin to prevent hypoglycemia and cerebral edema.

Euglycemic DKA (blood glucose <200 mg/dL with high anion gap ketoacidosis) is disproportionately driven by SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin), pregnancy, or prolonged fasting; SGLT2 inhibitors must be discontinued at least 3 to 4 days prior to elective major surgery.

Whipple's triad defines hypoglycemia; conscious patients are treated via the 'Rule of 15' (15 g rapid-acting carbohydrate, recheck in 15 minutes); severe unconscious hypoglycemia requires IV 50% Dextrose (D50W 25 g push) or Glucagon (1 mg IM/SC or 3 mg nasal powder); sulfonylurea-induced refractory hypoglycemia mandates hospital admission, IV dextrose, and subcutaneous Octreotide (50 mcg SC q8-12h) to suppress insulin secretion.

Last updated: October 2026

Spectrum of Acute Hyperglycemic Crises: DKA vs. HHS

Diabetic Ketoacidosis (DKA) and Hyperosmolar Hyperglycemic State (HHS) represent the two extreme poles of life-threatening acute metabolic decompensation in diabetes mellitus. While historically DKA was viewed as exclusive to type 1 diabetes and HHS to type 2 diabetes, significant clinical overlap occurs: up to 30% of patients present with features of both conditions.

Pathophysiologic Divergence

Diabetic Ketoacidosis (DKA) :

Absolute Insulin Deficiency : Triggered by omitted insulin, acute infection (pneumonia, UTI, sepsis), myocardial infarction, stroke, trauma, or pancreatitis. In the near-total absence of insulin, counterregulatory hormones ( glucagon , cortisol , epinephrine , and growth hormone ) surge unrestrained.

Uninhibited Lipolysis : Adipose tissue triglyceride breakdown is stimulated, flooding the portal circulation with free fatty acids (FFAs) .

Hepatic Ketogenesis : In the liver, the enzyme carnitine palmitoyltransferase-1 (CPT-1) is disinhibited. FFAs enter hepatic mitochondria and undergo accelerated beta-oxidation to acetyl-CoA, which is channeled into the synthesis of ketone bodies: acetoacetate , beta-hydroxybutyrate (beta-OHB) , and acetone.

Metabolic Acidosis : Beta-OHB and acetoacetate are strong organic acids (pKa ~4.0) that circulate fully dissociated, consuming serum bicarbonate and generating a high anion gap metabolic acidosis (Anion Gap = [Na+] - [Cl-] - [HCO3-] > 12 mEq/L).

Rapid Evolution : Develops acutely within <24 hours , with rapid onset of nausea, vomiting, abdominal pain (from visceral peritoneal stretching and prostaglandin release), and deep, rapid Kussmaul respirations to blow off carbon dioxide.

Hyperosmolar Hyperglycemic State (HHS) :

Relative Insulin Deficiency : Endogenous insulin secretion in type 2 diabetes is insufficient to stimulate peripheral glucose utilization in muscle and adipose tissue, but remains adequate to suppress adipose lipolysis and hepatic ketogenesis (only ~1/10th the concentration of insulin is required to block lipolysis as is needed for glucose disposal).

Massive Osmotic Diuresis : Severe, persistent hyperglycemia exceeds the renal proximal tubular resorptive capacity (typically >180-200 mg/dL). Unchecked glycosuria induces an unrelenting osmotic diuresis, leading to profound loss of water and electrolytes.

Extreme Hyperosmolality & Dehydration : Develops insidiously over days to weeks . By the time patients present, their fluid deficit is catastrophic ( 8 to 10 liters , or 100-200 mL/kg), serum glucose commonly exceeds 600 to 1,200 mg/dL, and effective serum osmolality surpasses 320 mOsm/kg , precipitating profound neurological depression (lethargy, stupor, focal seizures, coma). DIAGNOSTIC CRITERIA: DKA VS. HHS

• Diagnostic Criterion DKA (Mild / Mod / Severe) HHS
• ═════════════════════════════════════════════════════════════════════════════════════════
• Plasma Glucose (mg/dL) >= 200 mg/dL or known diabetes Markedly elevated: > 600 mg/dL
• Arterial pH < 7.30 (Severe: < 7.00) Normal: > 7.30
• Serum Bicarbonate (mEq/L) < 18 mEq/L (Severe: < 10) Normal: > 18 mEq/L
• Serum / Urine Ketones Strongly positive (Beta-OHB) Absent or trace
• Serum Anion Gap Elevated: > 10 to 12 mEq/L Variable (usually normal <= 12)
• Effective Serum Osmolality Variable (< 320 mOsm/kg) Hyperosmolar: > 320 mOsm/kg
• Mental Status Alert to drowsy Stupor or coma
• Typical Fluid Deficit Moderate: 4 to 6 Liters Profound: 8 to 10 Liters
• Onset Velocity Rapid: < 24 hours Insidious: Days to weeks
• ═════════════════════════════════════════════════════════════════════════════════════════
• Formula for Effective Serum Osmolality: 2 x [Measured Na+] + (Glucose / 18) [mOsm/kg]
• Formula for Serum Anion Gap: [Na+] - [Cl-] - [HCO3-] [mEq/L]
• The Three-Pillar Clinical Management Protocol

Managing acute hyperglycemic emergencies requires concurrent, synchronized execution of three physiological pillars: intravenous fluid expansion , potassium stabilization , and insulin administration .

Pillar 1: Fluid Resuscitation

The immediate priority is restoring intravascular volume, stabilizing blood pressure, and establishing renal perfusion:

First 2-4 hours : Infuse isotonic saline or a balanced crystalloid at 500 to 1,000 mL/hr in adults without renal or cardiac compromise; use smaller boluses (for example, 250 mL) with frequent reassessment in older adults, heart failure, or dialysis (2024 adult consensus).

Subsequent Hours : Calculate the corrected serum sodium to adjust for the osmotic shift of intracellular water into the extracellular space: Corrected [ Na + ] = Measured [ Na + ] + 1.6 × ( Glucose − 100 100 ) \text{Corrected } [\text{Na}^+] = \text{Measured } [\text{Na}^+] + 1.6 \times \left(\frac{\text{Glucose} - 100}{100}\right) Corrected [ Na + ] = Measured [ Na + ] + 1.6 × ( 100 Glucose − 100 ​ ) (Note: For glucose levels >400 mg/dL, a multiplier of 2.0 is often clinically applied).

If corrected sodium is normal (135-145 mEq/L) or elevated (>145 mEq/L) : Switch fluids to half-normal saline (0.45% NaCl) at 250 to 500 mL/hr to replace free water deficits.

If corrected sodium is low (<135 mEq/L) : Continue isotonic normal saline (0.9% NaCl) at 250 to 500 mL/hr.

The Glycemic Threshold for Dextrose Addition :

In DKA : When blood glucose drops below 250 mg/dL , add 5-10% dextrose to the IV fluids while maintaining the insulin infusion at a reduced rate (about 0.05 units/kg/hr). Blood glucose is kept near 200 mg/dL until ketoacidosis completely clears (2024 adult consensus).

In HHS : When blood glucose drops below 300 mg/dL , add 5% Dextrose (D5 0.45% NaCl) , titrating insulin to maintain blood glucose between 200 and 300 mg/dL until hyperosmolality resolves and mental status normalizes.

Clinical Rationale : Halting or reducing insulin before ketoacidosis resolves causes immediate relapse. Adding dextrose prevents hypoglycemia while allowing continued insulin infusion to close the anion gap. Furthermore, it prevents precipitous drops in intravascular osmolality that trigger cerebral edema .

Pillar 2: Potassium Management & The Absolute Safety Rule

Total body potassium is invariably depleted in both DKA and HHS due to urinary loss from osmotic diuresis and gastrointestinal losses. However, measured initial serum potassium is often normal or elevated because acidosis and insulin deficiency cause potassium to shift out of intracellular stores into the serum.

Caution

THE POTASSIUM SAFETY RULE (2024 ADULT CONSENSUS): DELAY INSULIN IF K+ < 3.5 Insulin drives potassium rapidly into cells via Na+/K+-ATPase activation, while rehydration dilutes serum potassium.

If serum potassium is < 3.5 mEq/L, HOLD THE INSULIN INFUSION . Start IV potassium replacement (about 10 mEq/hr) until serum K+ is > 3.5 mEq/L . Administering insulin to a patient with severe hypokalemia can trigger lethal ventricular arrhythmias, respiratory muscle paralysis, and cardiac arrest.

Potassium Triage Protocol :

Serum K+ < 3.5 mEq/L : HOLD INSULIN . Infuse potassium chloride at about 10 mEq/hr until K+ rises > 3.5 mEq/L. Then initiate insulin.

Serum K+ 3.5 to 5.0 mEq/L : Add 20 to 30 mEq potassium per liter of IV maintenance fluid (mix of 2/3 KCl and 1/3 KPO4 to replenish phosphate). Concurrently initiate insulin infusion. Target serum potassium: 4.0 to 5.0 mEq/L .

Serum K+ > 5.0 mEq/L : Do NOT add potassium to IV fluids. Initiate insulin infusion. Recheck serum potassium 2 hours after insulin starts, then every 4 hours; add potassium once levels fall below 5.0 mEq/L.

Pillar 3: Regular Insulin Administration & Titration

Administration Regimen :

Continuous IV infusion of Regular Insulin : Either an initial IV bolus of 0.1 units/kg followed by a continuous infusion of 0.1 units/kg/hr , OR a continuous infusion of 0.14 units/kg/hr without a bolus .

Target rate of glucose decline: 50 to 75 mg/dL per hour . If glucose fails to fall by at least 50 mg/dL in the first hour, verify IV line patency and double the insulin infusion rate every hour until steady glycemic reduction is achieved.

DKA Resolution Criteria (2024 adult consensus):

DKA is resolved when plasma ketone (beta-hydroxybutyrate) is <0.6 mmol/L AND venous pH is >= 7.3 or serum bicarbonate is >= 18 mEq/L ; ideally, blood glucose is also <200 mg/dL. (Note: Do not use the anion gap, which saline-related hyperchloremic acidosis can make misleading, or urine ketones, because beta-hydroxybutyrate converts to acetoacetate as the acidosis improves.)

Important

THE 2-HOUR SUBCUTANEOUS BASAL INSULIN OVERLAP MANDATE Intravenous regular insulin has a biological half-life of only 4 to 5 minutes. If the IV insulin infusion is abruptly terminated, the patient is left with zero circulating insulin, precipitating rebound ketoacidosis within 1 to 2 hours.

Clinicians must administer subcutaneous basal insulin (e.g., glargine, detemir, degludec) at least 2 hours prior to stopping the IV insulin infusion . If the patient is eating, subcutaneous rapid-acting prandial insulin should also be administered with a meal at the time of discontinuation.

Euglycemic Diabetic Ketoacidosis (euDKA)

Euglycemic DKA is defined as the presence of ketoacidosis (arterial pH <7.30, serum bicarbonate <18 mEq/L, elevated anion gap >12 mEq/L, positive serum beta-hydroxybutyrate >=3.0 mmol/L) with normal or only mildly elevated blood glucose (<200 mg/dL) .

Mechanism of SGLT2 Inhibitor-Induced euDKA

Pharmacologic Class : Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors ( canagliflozin, empagliflozin, dapagliflozin, ertugliflozin ).

Pathogenesis : By blocking SGLT2 in the proximal renal tubule, these agents induce continuous renal glycosuria (~70-100 g glucose/day excreted), artificially keeping blood glucose <200 mg/dL despite profound metabolic stress. Lower circulating glucose reduces pancreatic beta-cell insulin secretion, while concurrently stimulating pancreatic alpha cells to secrete glucagon . The resulting high glucagon-to-insulin ratio triggers massive lipolysis and hepatic ketogenesis.

Precipitating Triggers : Acute surgical stress, severe intercurrent infection, low-carbohydrate or ketogenic diets, alcohol ingestion, dehydration, or inappropriate reduction of exogenous insulin doses.

Preoperative Hold Guidelines :

Canagliflozin, Dapagliflozin, Empagliflozin: Withhold for at least 3 days (72 hours) prior to scheduled elective surgery.

Ertugliflozin: Withhold for at least 4 days (96 hours) prior to elective surgery.

Monitor serial venous blood gases, bicarbonate, and beta-hydroxybutyrate if patients on SGLT2 inhibitors become acutely ill, regardless of normal fingerstick glucose readings!

Acute Hypoglycemia: Triage, Rule of 15 & Toxicity Management

Hypoglycemia is the most common endocrine emergency, representing a major limiting factor in glycemic optimization for patients with diabetes.

Whipple's Triad & Diagnostic Stratification

True hypoglycemia is clinically established by Whipple's Triad :

• Symptoms consistent with low blood glucose;
• Documented low plasma glucose concentration (<70 mg/dL);
• Prompt resolution of symptoms following carbohydrate administration. ADA HYPOGLYCEMIA SEVERITY CLASSIFICATION

• Classification Glycemic Level Clinical Manifestations & Actions
• ═════════════════════════════════════════════════════════════════════════════════════════════
• Level 1 < 70 mg/dL and >= 54 mg/dL Autonomic warning signs (tremor, sweating);
• (Alert Value) Patient self-treats with fast carbohydrates

• Level 2 < 54 mg/dL Clinically significant hypoglycemia;
• (Significant) Neuroglycopenic symptoms begin

• Level 3 No specific glucose threshold Severe cognitive impairment requiring external
• (Severe) (typically < 40-50 mg/dL) assistance for recovery (coma, seizure)
• ═════════════════════════════════════════════════════════════════════════════════════════════
• Symptoms: Neurogenic vs. Neuroglycopenic

Autonomic / Neurogenic Symptoms (mediated by sympathetic nervous system and epinephrine release): Diaphoresis, tremors, tachycardia, palpitations, anxiety, hunger, and pallor.

Neuroglycopenic Symptoms (resulting from neuronal glucose deprivation): Confusion, irritability, dizziness, blurred vision, dysarthria, ataxia, behavioral changes, seizures, and loss of consciousness.

Hypoglycemia Unawareness : Recurrent episodes of hypoglycemia blunt the autonomic sympathoadrenal response, eliminating early neurogenic warning signs. Patients transition directly into severe neuroglycopenia or coma without warning.

Conscious Management: The "Rule of 15"

For conscious patients able to swallow safely (Level 1 and Level 2 hypoglycemia):

Administer 15 to 20 grams of rapid-acting simple carbohydrate :

• 4 ounces (1/2 cup) of fruit juice or regular (non-diet) soda;
• 3 to 4 commercial glucose tablets;
• 1 tube of glucose gel;

5 to 6 hard candies. (Avoid complex carbohydrates or fat-rich foods like chocolate or peanut butter, as fats delay gastric emptying and slow glucose absorption).

Wait 15 minutes and recheck fingerstick blood glucose.

If blood glucose remains < 70 mg/dL , administer another 15 grams of fast-acting carbohydrate.

Once blood glucose normalizes (>=70 mg/dL), have the patient consume a complex carbohydrate and protein snack or meal (e.g., sandwich, crackers with cheese) to replenish hepatic glycogen stores.

Emergency Management of Severe Unconscious Hypoglycemia

For unconscious, seizing, or uncooperative patients unable to ingest oral carbohydrates:

Intravenous Access Available : Administer 50% Dextrose in Water (D50W) 25 grams (50 mL) via slow IV push over 2 to 3 minutes. Follow with an IV infusion of 5% or 10% dextrose if needed to maintain glucose >100 mg/dL.

No Intravenous Access :

Glucagon 1 mg intramuscular (IM) or subcutaneous (SC) : Mobilizes hepatic glycogen stores; works within 10 to 15 minutes. Note: Glucagon is ineffective in patients with depleted glycogen stores (prolonged fasting, advanced cirrhosis, starvation, alcohol-induced hypoglycemia).

Intranasal Glucagon (Baqsimi) 3 mg single spray : Administered into one nostril; passively absorbed across the nasal mucosa without requiring active inhalation, effective even in nasal congestion.

Sulfonylurea-Induced Prolonged Hypoglycemia

Pathophysiology : Sulfonylureas ( glyburide, glimepiride, glipizide ) stimulate continuous, glucose-independent insulin secretion by binding to the sulfonylurea receptor (SUR1) on pancreatic beta cells. Glyburide has active metabolites that accumulate in renal impairment, causing protracted hypoglycemia lasting 24 to 72 hours.

The Dextrose Trap : Administering repeated IV dextrose boluses provides substrate that stimulates further endogenous insulin release from beta cells, precipitating "rebound" hypoglycemia.

Mandatory Inpatient Management :

Hospital Admission : Mandatory observation for at least 24 to 48 hours with continuous telemetry and serial hourly glucose checks.

Octreotide Therapy : Octreotide (50 mcg SC every 8 to 12 hours) . Octreotide is a synthetic somatostatin analogue that directly binds to somatostatin receptor subtype-2 (SSTR2) on beta cells, hyperpolarizing the cell membrane, closing voltage-gated calcium channels, and completely suppressing endogenous insulin secretion .

Loading diagram... Clinical Management Algorithm for Acute Hyperglycemic Emergencies (DKA & HHS)